Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Roll-over Safety Study of AGI-003 (arverapamil) in IBS-D
2007-003849-32Phase 3Completed
- Sponsor
- AGI Therapeutics plc
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dexverapamil in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by AGI Therapeutics plc. Primary endpoint: Long-term safety of AGI-003. Started Aug 2007; status: completed.
02
Drugs
dexverapamil
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2007-003849-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003849-32.